Regeneron Lynozyfic monotherapy in newly diagnosed multiple myeloma impressive responses

 All three dose groups (50 mg, 100 mg and 200 mg) showed impressive monotherapy efficacy, with VGPR+ (very good partial response or better) of ≥70% despite limited follow-up; evidence shows that these responses are expected to deepen over time

Across all dose groups, 95% (19 of 20 patients) of all evaluable VGPR+ patients achieved minimal residual disease negative status

Data featured in an ASH oral presentation; LINKER-MM4 is the first clinical trial to evaluate a BCMAxCD3 bispecific monotherapy in NDMM and is part of a broad clinical development program evaluating Lynozyfic-based regimens in earlier lines of treatment

https://www.manilatimes.net/2025/12/08/tmt-newswire/globenewswire/lynozyfic-linvoseltamab-monotherapy-in-newly-diagnosed-multiple-myeloma-ndmm-shows-impressive-responses-supporting-rationale-as-a-potential-foundation-in-frontline-treatment/2238548